Paris, March 25, 2010 – Cellectis (Alternext: ALCLS), the French genome
engineering specialist, announced today that it has granted Boehringer Ingelheim
a license on the European Patents N°EP 182 6215, EP 682 111, EP 682 112 and
EP 419 621 to obtain, breed and utilize animal models in pharmaceutical research
throughout Europe. This license covers an Institut Pasteur technology for
introducing new features in genomes, for which Cellectis has an exclusive license.
The terms of the contract have not been disclosed.
“The technologies developed at the Institut Pasteur have provided the
pharmaceutical industry, among others, with highly efficient tools that have a wide
variety of applications, in research as well as in drug development, and for many
different diseases. We’re proud that Boehringer Ingelheim recognizes the value of
such technologies,” said Cellectis’ CEO André Choulika. “We will continue to
pursue appropriate recognition of these patents within the healthcare industry and
seek to receive the proper value for our own patents in the same way, to fund our
research programs.”
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets
innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA,
with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more
than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies
across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or
pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in
Paris and has secured over €70 million in funding since inception.
More information at www.cellectis.com
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that
relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and
assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties
include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be
continued growth in the relevant market and demand for the Company’s products, new products or technological
developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in
connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in
connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa no. 07-023 on
January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements
above.
